Thank you, Mr. Chairperson.
Thanks to all of you for your presentations.
I want to start with the Auditor General.
Madam Fraser, you focus on some of the deficiencies in the system with respect to post-market surveillance. And you express hope that the new safety plan and the legislation that was just tabled this week will help in that regard. I want to get to that. But I first want to ask if you have evidence to suggest that we've actually done a proper job in terms of pre-market surveillance.
You say that without post-market surveillance there are consequences for the health and safety of Canadians because of exposure to unsafe drugs and products. If there are unsafe products getting to market, then maybe we haven't done a proper job in terms of actual pre-market surveillance.
You mentioned money. One indicator is that more of the money available has gone to pre-market than post-market. But has that produced any better results? Are we producing any safer products? Are there fewer incidents in terms of drugs on the market with respect to reactions and so on?